ORLANDO, FL Mar. 11, 2018 — American Heart Association CEO Nancy Brown issued the following statement today following disclosure by Sanofi and Regeneron that the companies are making commitments to expand access to lifesaving medicine.
“Last week the American Heart Association convened forty global healthcare leaders in Washington, D.C. and challenged the group to make meaningful commitments to improving access to health care.
We believe that ensuring patients have affordable access to the care they need is a moral obligation, and we are heartened by Sanofi and Regeneron's substantial commitment to reduce the costs of their proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor as part of this larger effort to shift the focus to the value of treatment and not simply its costs.
As a catalyst for meaningful change, the American Heart Association is committed to continuing its leadership in this conversation – by convening, encouraging and supporting progressive steps and by encouraging all others to similarly step forward with new and innovative solutions to improve patient care.”
About the American Heart Association
The American Heart Association is devoted to saving people from heart disease and stroke – the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.
Maggie Francis, 214-706-1382, email@example.com